No Licensing Deal For Theravance

GlaxoSmithKline PLC (GSK) will not license Theravance Inc.'s (THRX) gastrointestinal disorder treatment. Shares of GlaxoSmithKline slipped 39 cents to close at $53.07 while Theravance's stock plunged $3.37 to close at $28.38.